Published Aug 08, 2018

Harbour BioMed inks $350 million deal for rights to A167

Member News

Related or similar articles

May 17, 2024

Streamlining Procurement: Labshares Partners with Labviva for Enhanced Access and Efficiency

In the fast-paced world of biotech innovation, easy access to crucial resources is vital for research success. That's why Labshares is excited to share news of our partnership with Labviva, a top procurement platform reshaping how scientists obtain l
Labshares News
April 28, 2020

Labshares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research​

Labshares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies...
Labshares News
August 8, 2018

Harbour BioMed inks $350 million deal for rights to A167

USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News